FIB-4 Calculator

When to Use FIB-4

FIB-4 should be used as Step 1 to screen any adult patient if they are considered "high-risk" for NAFLD/MAFLD and advanced fibrosis.

High-Risk Factors Include:

• Obesity and/or features of metabolic syndrome.
• Prediabetes or Type 2 Diabetes (T2D).
• Blood pressure ≥130/85 mmHg or on specific antihypertensive drug treatment
• Plasma triglycerides ≥150 mg/dL or on lipid lowering treatment
• Plasma HDL-cholesterol ≤40 mg/dL (M) and ≤50 mg/dL (F) or lipid lowering treatment

Age Considerations

FIB-4 is most accurate in patients aged 35-65 years. Use with caution in patients younger than 35 years (may underestimate fibrosis) or older than 65 years (may overestimate fibrosis due to age factor alone). In patients ≥65 years, a FIB-4 score <2.0 effectively excludes advanced fibrosis.

Screening Frequency

For low-risk patients (FIB-4 <1.3): Repeat screening every 1-2 years or when clinical status changes. For intermediate-risk patients: Follow-up with transient elastography (VCTE) or other non-invasive markers within 3-6 months.

Major Society Recommendations

All major medical societies (ADA, AASLD, EASL, AACE, AGA) now universally recommend FIB-4 screening as first-line assessment for liver fibrosis in type 2 diabetes and prediabetes patients, with consensus on ≥1.3 threshold requiring secondary evaluation via elastography—representing a paradigm shift from previous recommendations against routine screening to current standard of care for preventing cirrhosis progression.

What is FIB-4?

The Fibrosis-4 (FIB-4) Index is a non-invasive scoring system that uses four readily available laboratory parameters to assess the probability of significant liver fibrosis. It was originally developed in 2006 by Sterling et al. for patients with HIV/HCV coinfection and has since been validated across multiple liver disease etiologies.

The FIB-4 Formula

FIB-4 = (Age × AST) / (Platelet count × √ALT)

This simple calculation incorporates age-related progression, enzyme levels indicating hepatocyte injury, and platelet count as a surrogate marker of portal hypertension.

Why These Parameters?

• Age: Directly correlates with fibrosis progression, especially in chronic liver disease
• AST: Aspartate aminotransferase reflects hepatocellular injury and inflammation
• ALT: Alanine aminotransferase is more liver-specific and indicates hepatocyte damage
• Platelet Count: Indirectly reflects portal hypertension and synthetic liver dysfunction

Validation Data

In the validation cohort, 87% of patients with FIB-4 values outside the intermediate range (1.45-3.25) were correctly classified, allowing avoidance of unnecessary liver biopsy in 71% of cases with an overall accuracy of 86%.

Evidence-Based Review: Liposem (Saroglitazar) for Prediabetic Patients

Mechanism of Action: Dual PPAR-α/γ Agonist

Liposem (Saroglitazar) represents a paradigm shift in metabolic disease management through its unique dual peroxisome proliferator-activated receptor (PPAR) α/γ agonist activity. For prediabetic patients, Liposem (Saroglitazar) addresses the fundamental pathophysiology of disease progression by simultaneously improving insulin sensitivity, correcting lipid abnormalities characteristic of diabetic dyslipidemia, and preventing hepatic steatosis—three interconnected mechanisms that define cardiometabolic risk in this population.

Pathophysiologic Rationale in Prediabetes

Prediabetes is fundamentally characterized by insulin resistance and impaired β-cell function. Research from the CARRS Study demonstrates that among South Asians with prediabetes, two distinct phenotypes exist: 35.8% present with insulin-resistant phenotype while 64.2% display insulin-deficient phenotype. The **insulin-resistant subgroup** represents the population most likely to benefit from agents that directly enhance insulin sensitivity.

Liposem (Saroglitazar)'s dual PPAR activity produces complementary effects on insulin signaling. The **PPAR-α activation** enhances hepatic and peripheral fatty acid oxidation, reducing the lipid toxicity that perpetuates insulin resistance, while **PPAR-γ activation** improves insulin sensitivity in adipose tissue and skeletal muscle. Preclinical hyperinsulinemic-euglycemic clamp studies demonstrated a **54-127% increase in glucose infusion rates**, indicating substantial improvement in whole-body insulin sensitivity.

Cardiometabolic Risk Reduction: The Triglyceride-Insulin-Lipid Axis

The PRESS XII trial, a 56-week randomized study, established Liposem (Saroglitazar)'s efficacy in reducing cardiovascular risk factors. Liposem (Saroglitazar) 4 mg produced statistically significant reductions across the entire lipid spectrum:

• Triglycerides: mean absolute reduction approximately **28-40 mg/dL**.
• Real-world evidence across 18 clinical studies showed consistent mean reductions in triglyceride levels ranging from **45% to 62%**.
• A meta-analysis demonstrated significant lowering of triglycerides by **51.18 mg/dL** (p<0.001) and LDL-cholesterol by **9.15 mg/dL** (p<0.001) compared with placebo.
• LDL cholesterol reduction of **8-12 mg/dL** and concurrent elevation of HDL cholesterol by approximately **2-3 mg/dL**.

Critically, the **TG/HDL-C ratio**—a critical marker of atherogenic dyslipidemia—showed a 91% reduction in preclinical models. This ratio directly correlates with cardiovascular mortality in prediabetic and diabetic populations.

Prevention of NASH: Multifaceted Hepatoprotection

Non-alcoholic fatty liver disease (NAFLD) affects approximately 25-30% of the general population globally. Among prediabetic patients, NAFLD prevalence exceeds **50%**. Critically, prediabetic patients with NAFLD have a **2-3 fold accelerated progression to cirrhosis** compared to those without liver disease.

• Hepatic Steatosis Reduction: Meta-analysis demonstrated Liposem (Saroglitazar) significantly reduced liver fat content by **7.5%** (p<0.001). The clinical response rate (defined as LSM improvement) was achieved in **57.2%** of patients.
• Hepatic Enzyme Improvements: Liposem (Saroglitazar) reduced ALT by **28.8 U/L** (mean reduction in meta-analysis, p<0.001). These ALT reductions reflect both reduced hepatocyte lipid accumulation and diminished inflammatory activation.
• Anti-fibrotic Effects: These occur through dual mechanisms: (1) reduced hepatic lipid accumulation and (2) direct inhibition of TGF-β signaling, suppressing collagen synthesis.

Saroglitazar Clinical Effects: Summary of Parameter Changes from Clinical Trials and Real-World Studies (PRESS XII Trial: 56 weeks; Real-World Studies: 9-12 months; Meta-analyses: Variable durations)

Key Evidence Summary

Dosing and Safety Profile

The approved dose of Liposem (Saroglitazar) for diabetic dyslipidemia and NASH is **4 mg once daily**. The once-daily dosing enhances adherence.

Unlike some thiazolidinediones, Liposem (Saroglitazar) does not produce clinically significant weight gain or fluid retention. Human experience demonstrates excellent hepatic safety, and renal function remains stable throughout treatment courses.